Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. - Wikidata - wikimedia - TriplyDB

Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer.

Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer.

http://www.wikidata.org/entity/Q46111623

about

Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy.Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer.Pancreatic cancer: disease dynamics, tumor biology and the role of the microenvironment.Tumor immunity and survival as a function of alternative neopeptides in human cancer.Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk.Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas.Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.The perfect personalized cancer therapy: cancer vaccines against neoantigens.Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions.Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond DNA repair defects and implications for immunotherapy KRAS RENAISSANCE(S) in Tumor Infiltrating B Cells in Pancreatic Cancer MUC16 mutations improve patients' prognosis by enhancing the infiltration and antitumor immunity of cytotoxic T lymphocytes in the endometrial cancer microenvironment Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients TSNAdb: A Database for Tumor-specific Neoantigens from Immunogenomics Data Analysis Personalized identification of tumor-associated immunogenic neoepitopes in hepatocellular carcinoma in complete remission after sorafenib treatment

P2860

Q47209071-5EF164EC-48BA-42BA-AECB-D86B25A2BAF9 Q47701712-A9E78FB7-8281-4FB6-AA33-EADC2D938DBD Q49787327-F5C3EFD0-9602-4849-8DF7-E5929161AA74 Q50020805-079FC2A2-3E19-4D20-A020-4D48758F93F4 Q52333009-2F1E9BCA-A602-4CAE-94F1-FF20BC38C515 Q52607320-B201E40E-1194-46CD-959E-C18354A13A3D Q54965295-F2EB2028-379D-4666-8A71-89346F5D5703 Q55001351-2D91974A-AF58-4044-A4B9-D676D8E4FF79 Q55240544-D127478A-1ACB-41C2-935D-97B8F7EB8844 Q55287125-FCD17B1D-D8B1-4B92-892F-79BEA9E21F94 Q56890107-B36B9ED5-B6FD-4B77-86C4-572364EA2414 Q56891609-E31E286C-79D5-4ECB-B720-C169B0B442A5 Q57057014-0EF3E266-9381-4AC8-AE53-36DC45512574 Q57072901-199EF94B-C551-4016-9EBD-BEF2D28E4FF5 Q57135123-2592B6BA-2E96-4317-B88D-84CFF7F0314D Q57810732-ACC0B8BE-44D1-4516-93E3-49E66D9DE1E7 Q58736099-CC0E2A66-E426-4CCB-BA4E-69F608654970 Q59136533-97FF806B-1F60-49EC-8B40-DB3F7E6F53E5

P2860

Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer.

http://www.wikidata.org/entity/Q46111623

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Identification of unique neoan ...... urvivors of pancreatic cancer.

@en

Identification of unique neoan ...... urvivors of pancreatic cancer.

@nl

type

label

Identification of unique neoan ...... urvivors of pancreatic cancer.

@en

Identification of unique neoan ...... urvivors of pancreatic cancer.

@nl

prefLabel

Identification of unique neoan ...... urvivors of pancreatic cancer.

@en

Identification of unique neoan ...... urvivors of pancreatic cancer.

@nl

P1433

Q46111623-2B7D60D4-CE4C-465B-BFC5-9D9033CA45F7

P1476

Q46111623-4F3F9940-8541-4BE1-935C-0F4D830E37CF

P2093

Q46111623-007AC7F0-0CC8-45A7-A140-99B6A28355A9

Q46111623-02ABB4E9-2796-43E1-8FBD-297A3D17C0E7

Q46111623-03B5507F-B1F7-4481-A395-C111C6067D2A

Q46111623-07C38B5D-2A67-4A48-A5E6-F261D2FCB538

Q46111623-07D902BF-2876-44FC-87B4-8FAD83376BBA

Q46111623-0A3D97B5-AF43-4E98-89FA-3E47019A4041

Q46111623-12BAC203-FA24-46FB-989A-1CB69B0D5C32

Q46111623-1EE9EC25-7D56-44B5-A074-20FA2B9B020B

Q46111623-2186CD8D-AB06-49C9-AB22-CB15CA8CD797

Q46111623-2239AB0E-0698-4216-B4DA-37D8BFBAF420

P2860

Q46111623-066C558C-AA8F-4AA9-9463-3EB6E241AA87

Q46111623-06A154BF-8425-4BFC-BCAB-59412F686016

Q46111623-1B20BC7B-9AD8-4F2C-A033-4030ECB79D01

Q46111623-1BA447BA-F10B-4C91-8822-638894F40F61

Q46111623-230F67B3-7875-4B90-A243-524DCD8ABAAE

Q46111623-2B91E6E4-40D9-45BA-A84D-900D4C628D4F

Q46111623-3A8C3D7A-EABC-4D2E-8645-C34541E7B3F4

Q46111623-42200653-4FDD-43F5-A9FF-5E488A473187

Q46111623-48118CB4-B01E-45EA-BDF8-A56712190B53

Q46111623-5911C202-C171-440E-881E-AD5981275247

P2888

Q46111623-E72AA0C2-2F11-4351-9E2A-A37CEEF90EC3

P304

Q46111623-2F99B70C-988B-497A-8319-90D266B687D5

P31

Q46111623-939415FB-05C2-4402-AB00-F096F6C7E705

P356

Q46111623-888FCE5F-70D7-46ED-BA8E-114C9B11A60A

P407

Q46111623-95DD9016-680D-4686-9D09-C3AC2E2EB2F8

P433

Q46111623-5919B18E-42B0-444F-A74E-A5910D1DAA7C

P478

Q46111623-20328B5E-A84E-4568-84B5-DF192DFC3693

P50

Q46111623-96B531FE-530A-417E-B59B-EF216C953DED

Q46111623-978E121B-8524-4EC7-BF1F-6B147BD1E2F2

Q46111623-9CAB8A1A-1FFD-401D-A9CD-E16A6BC1535B

Q46111623-BDC0FEDC-8F48-462A-B490-E4BEC64DE44E

P577

Q46111623-5C78DFFE-7BEE-4A36-BBD7-76AECF1351B0

P698

Q46111623-7C550C7A-DBBA-4FBD-8402-4E8F34AD7555

P932

Q46111623-42190634-838D-44CF-BC7B-980FF6F25651

P356

P1433

P1476

Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer

@en

P2093

ARC-Net Centre for Applied Research on Cancer

http://www.w3.org/2001/XMLSchema#string

Arnold J Levine

http://www.w3.org/2001/XMLSchema#string

Austin Hospital

http://www.w3.org/2001/XMLSchema#string

Australian Pancreatic Cancer Genome Initiative

http://www.w3.org/2001/XMLSchema#string

Bankstown Hospital

http://www.w3.org/2001/XMLSchema#string

Benjamin D Greenbaum

http://www.w3.org/2001/XMLSchema#string

Benjamin Medina

http://www.w3.org/2001/XMLSchema#string

Brian Herbst

http://www.w3.org/2001/XMLSchema#string

Charles Ian Ormsby Cary

http://www.w3.org/2001/XMLSchema#string

Daniel K Wells

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Quantifying selection in immune receptor repertoires.

Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen.

Pathobiological implications of MUC16 expression in pancreatic cancer.

Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16.

Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets.

Microbiome and Anticancer Immunosurveillance.

Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer.

MUC16-mediated activation of mTOR and c-Myc reprograms pancreatic cancer metabolism.

P2888

P304

512-516

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NATURE24462

http://www.w3.org/2001/XMLSchema#string

P407

P433

7681

http://www.w3.org/2001/XMLSchema#string

P478

551

http://www.w3.org/2001/XMLSchema#string

P50

Christine A Iacobuzio-Donahue

Martin Smoragiewicz

P577

2017-11-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29132146

http://www.w3.org/2001/XMLSchema#string

P932

6145146

http://www.w3.org/2001/XMLSchema#string